Company: PFSA
Filing Date: 2025-02-12
Form Type: S-4/A
Source: 0001213900-25-012354
Chunk: 287

Company: Profusa, Inc.
Filing Date: 2025-02-12
Form: S-4/A
Chunk 287
---
 both insulin using and non -insulinusing Type 2 patients in 2027, growing to 950,000 patients with implied associated market penetration rate of 2% by 2030. 11,12Consideration was given to competitive landscape today as well as timing of reimbursement and accounted for in Profusa’s penetration rate assumptions. 13As Profusa’s cost of goods are relatively favorable, Profusa assumed that pre -reimbursementadoption can be a reasonable path to early usage through a subscription model with monthly payments. 14,15 •Additional key assumptions regarding Lumee Glucose include: •Profusa completes clinical studies in Europe and achieves CE mark for Type 2 Diabetes in 2026. •The products average penetration rate for European Glucose sales in 2026 is 0.06%. ____________ 4https://www.mddionline.com/diabetes/look -competitive-landscape-diabetes-devices 5https://www.businesswire.com/news/home/20170519005456/en/According -to-THE-SAGE-GROUP-Peripheral-Artery-Disease- PAD -Afflicts-28-Million-Western-Europeans-and-4.2 -Million-Suffer-From-Critical-Limb-Ischemia-CLI— Numbers exclude UK which no longer honors CE mark 6https://www.businesswire.com/news/home/20170519005456/en/According -to-THE-SAGE-GROUP-Peripheral-Artery-Disease- PAD -Afflicts-28-Million-Western-Europeans-and-4.2 -Million-Suffer-From-Critical-Limb-Ischemia-CLI— Numbers exclude UK which no longer honors CE mark 7https://onlinelibrary.wiley.com/doi/abs/10.1002/hpm.2669 8Medtech 360 Report. Peripheral Vascular Devices Market Analysis US 2019 9Medtech 360 Report. Peripheral Vascular Devices Market Analysis US 2019 10https://journals.viamedica.pl/clinical_diabetology/article/view/61700 11https://www.health.com/condition/type -2-diabetes/12 -myths-about-insulin-and-type-2-diabetes 12https://accisstoolkit.haiweb.org/wp -content/uploads/2020/10/Estimate -of-Insulin-Use-in-Type-2-Diabetes1.pdf 13https://www.liebert